v3.26.1
Financial Assets and Liabilities - Additional Information (Detail)
€ / shares in Units, € in Millions, $ in Millions
1 Months Ended 6 Months Ended
May 06, 2026
shares
Sep. 03, 2024
USD ($)
Multiple
Sep. 30, 2024
EUR (€)
XBB
Sep. 30, 2024
USD ($)
XBB
Sep. 30, 2023
EUR (€)
Multiple
XBB
Sep. 30, 2023
USD ($)
Multiple
XBB
Mar. 31, 2022
EUR (€)
Mar. 31, 2022
USD ($)
Jun. 30, 2026
EUR (€)
shares
Dec. 31, 2025
€ / shares
Disclosure of detailed information about financial instruments [line items]                    
Bore Interest Rate             2.25% 2.25%    
Carrying amount of royalty funding liabilities | €                 € 301.8  
Fair value of royalty funding liabilities | €                 € 303.0  
Share price | € / shares                   € 48.9
Royalty Pharma U.S. Skytrofa [member]                    
Disclosure of detailed information about financial instruments [line items]                    
Funding received in exchange of royalty payments           $ 150.0        
Funding received in exchange of royalty payments           150.0        
Net proceeds after deduting offering expenses         € 136.3 $ 146.3        
Net revenue from sales interest payment in percentage in exchange for funding         9.15% 9.15%        
Royalty payment beginning period         Jan. 01, 2025 Jan. 01, 2025        
Royalty payment ending period         Dec. 31, 2031 Dec. 31, 2031        
Amount multiplied to purchase price minus revenue interest payments paid to purchaser on effective date of buy-out notice as buyout amount | XBB         1.925 1.925        
Amount multiplied to purchase price minus revenue interest payments paid to purchaser on effective date of buy-out notice provided on or prior to period as buyout amount | XBB         1.65 1.65        
Royalty Pharma U.S. Skytrofa [member] | Bottom of range [member]                    
Disclosure of detailed information about financial instruments [line items]                    
Multiple of the purchase price were royalty payment will cease | Multiple         1.65 1.65        
Royalty Pharma U.S. Skytrofa [member] | Top of range [member]                    
Disclosure of detailed information about financial instruments [line items]                    
Multiple of the purchase price were royalty payment will cease | Multiple         1.925 1.925        
Royalty Pharma U.S. Yorvipath [member]                    
Disclosure of detailed information about financial instruments [line items]                    
Funding received in exchange of royalty payments   $ 150.0                
Funding received in exchange of royalty payments       $ 150.0            
Net proceeds after deduting offering expenses     € 134.2 $ 148.2            
Net revenue from sales interest payment in percentage in exchange for funding   3.00%                
Royalty payment ending period   Dec. 31, 2029                
Amount multiplied to purchase price minus revenue interest payments paid to purchaser on effective date of buy-out notice as buyout amount | XBB     2 2            
Amount multiplied to purchase price minus revenue interest payments paid to purchaser on effective date of buy-out notice provided on or prior to period as buyout amount | XBB     1.65 1.65            
Royalty Pharma U.S. Yorvipath [member] | Bottom of range [member]                    
Disclosure of detailed information about financial instruments [line items]                    
Multiple of the purchase price were royalty payment will cease | Multiple   1.65                
Royalty Pharma U.S. Yorvipath [member] | Top of range [member]                    
Disclosure of detailed information about financial instruments [line items]                    
Multiple of the purchase price were royalty payment will cease | Multiple   2                
Convertible Senior Notes [Member]                    
Disclosure of detailed information about financial instruments [line items]                    
Borrowings interest rate 2.25%                  
Convertible ordinary shares | shares 3,635,813               3,635,813  
Principal amount               $ 575.0    
Borrowings redemption period May 6, 2026                  
Proceeds from issue of bonds, notes and debentures             € 503.3 $ 557.9    
Borrowings, maturity 2028                  
Fixed interest rate [member] | Convertible Senior Notes [Member]                    
Disclosure of detailed information about financial instruments [line items]                    
Borrowings interest rate 2.25%             2.25%